COMBINATION VACCINATION for kidney cancer

COMBINATION CANCER VACCINATION

http://www.ncbi.nlm.nih.gov/pubmed/18060404

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.

Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE.

Oxford BioMedica (UK) Ltd, The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK. r.harrop@oxfordbiomedica.co.uk

Abstract

Modified vaccinia Ankara (MVA) encoding the tumor antigen 5T4 (TroVax) has been evaluated in an open label phase II study in metastatic colorectal cancer patients. The primary objective was to assess the safety and immunogenicity of TroVax injected before, during and after treatment with 5-fluorouracil, leukovorin and irinotecan. TroVax was administered to 19 patients with metastatic colorectal cancer. Twelve patients had blood samples taken following each of the six injections and were considered to be evaluable for assessment of immunological responses. Both antibody and cellular responses specific for the tumor antigen 5T4 and the viral vector MVA were monitored throughout the study. Administration of TroVax alongside chemotherapy was safe and well tolerated with no SAEs attributed to the vaccine and no enhancement of chemo-related toxicity. Of the 12 patients who were evaluable for assessment of immune responses, ten mounted 5T4-specific antibody responses with titers ranging from 10 to > 5,000. IFNgamma ELISPOT responses specific for 5T4 were detected in 11 patients with frequencies exceeding one in 1,000 PBMCs in five patients. Eight patients presented with elevated circulating CEA concentrations, six of whom showed decreases in excess of 50% during chemotherapy and four had CEA levels which remained stable for > 1 month following completion of chemotherapy. Of the 19 intention to treat (ITT) patients, one had a CR, six had PRs and five had SD. Potent 5T4-specific cellular and/or humoral immune responses were induced in all 12 evaluable patients and were detectable in most patients during the period in which chemotherapy was administered. These data demonstrate that TroVax can be layered on top of chemotherapy regimens without any evidence of enhanced toxicity or reduced immunological or therapeutic efficacy.

PMID: 18060404 [PubMed - indexed for MEDLINE]


ONCO VIRUS QUIZ:  http://www.science-projects.com/oncoquiz.htm


***  HERPES VIRUS AND CANCER (und KREBS) ***

Beschreibung (Re: Nachweis):
http://de.wikipedia.org/wiki/Zytomegalievirus

A sore throat is common!!!
http://en.wikipedia.org/wiki/Cytomegalovirus

Stimmt es, daß Herpes sich der Interferon Immunantwort bemächtigt?
Does Herpes URSURP the inferon reaction?
HV-5 (Cytomegalovirus): Mononucleosis, eye, kidney, brain and congenital infections
http://www.science-projects.com/V21.htm Herpes A type that breaks the rules!

But Interferon Injections HELP! 
http://content.karger.com/ProdukteDB/produkte.asp?Doi=9998


Rabbits:
Natural (good) / Recombinant (bad) Interferon:  http://www.iovs.org/cgi/reprint/25/7/874.pdf
Monkeys

July 1984 Natural human leukocyte interferon (natural HuIFN-a) and
recombinant leukocyte A interferon (recombinant A HuIFN-
a) were tested for prophylactic and/or therapeutic effects in
reducing the severity of keratitis in rabbit and monkey eyes
infected with McKrae strain herpesvirus. The results showed
that the two interferons acted differently in the rabbit eye;
combined prophylactic and therapeutic administration of
natural interferon mitigated the disease, while recombinant
interferon had no effect. In monkeys, the two interferons
acted similarly. Combined prophylactic and therapeutic ad-
ministration reduced disease findings, while therapeutic ad-
ministration alone had no effect. Thus, studies in rabbits are
not accurate predictors of primate study results;


***** VIRUSES and CANCER ??? **********


COMBINATION VACCINATION for kidney cancer

http://en.wikipedia.org/wiki/TroVax#Renal_cell_carcinoma

http://clinicaltrials.gov/ct2/show/NCT00083941

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
This study has been completed  (IN 2008!).
First Received: June 3, 2004   Last Updated: July 31, 2008   History of Changes
Sponsor:     Oxford BioMedica  Collaborators:     Columbia University
ORION Clinical Services   Information provided by:     Oxford BioMedica
ClinicalTrials.gov Identifier:     NCT00083941

The purpose of this study is to test the safety of an investigational vaccine called TroVax when given in conjunction with Interleukin-2 (IL-2) treatment. TroVax is the experimental product in this trial and its value as a medicine has not yet been proven. Interleukin-2 (IL-2) is standard treatment for your cancer, which means that you could receive it even if you choose not to participate in this study. TroVax is being studied as a possible treatment for patients with cancer of the kidney.

TroVax belongs to a class of medicines called a vaccine. A vaccine helps the body's immune system to recognize and kill foreign invading organisms effectively. It is believed that one of the reasons why cancer can spread through the body is that the immune system cannot recognize them as being different from normal tissues and therefore cannot kill the cancer cells. A vaccine that alerts the immune system to the presence of cancer cells in the body could lead to the immune system being able to target and kill those cancer cells effectively. This trial is of a completely new way of trying to treat cancer in the future by the use of vaccination injections. TroVax consists of a virus that has been changed so that it is no longer infectious and carries a gene for a protein called 5T4. This protein is carried by many kidney cancer calls. When the virus is injected, it makes the protein, and the body's immune system is then able to recognize this protein and kill the cells that have it (i.e. the cancer cells).

The purpose of this study is to assess the safety and tolerability of TroVax injections and to understand whether TroVax could make such an immune response happen in patients with renal cell cancer while receiving Interleukin-2 (IL-2). This study will also observe and monitor any side effects experienced in patients who receive TroVax while being treated with IL-2.

Condition     Intervention     Phase
Carcinoma, Renal Cell     Biological: TroVax in combination with IL-2   Phase II

Study Type:     Interventional
Study Design:     Allocation: Non-Randomized
Control: Historical Control
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label  Primary Purpose: Treatment
Official Title:     Clinical Trial Phase II (Single Centre Study) : A Preliminary Study of the Safety, Immunogenicity, and Clinical Efficacy of TroVax Given in Conjunction With Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer